219 related articles for article (PubMed ID: 34178093)
1. Bimekizumab: the new drug in the biologics armamentarium for psoriasis.
Freitas E; Torres T
Drugs Context; 2021; 10():. PubMed ID: 34178093
[TBL] [Abstract][Full Text] [Related]
2. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
3. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.
Ruggiero A; Potestio L; Camela E; Fabbrocini G; Megna M
Psoriasis (Auckl); 2022; 12():127-137. PubMed ID: 35707807
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab for the Treatment of Psoriasis.
Freitas E; Blauvelt A; Torres T
Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of IL-17A and IL-17F in psoriatic disease.
Iznardo H; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211037846. PubMed ID: 34408825
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Armstrong A; Fahrbach K; Leonardi C; Augustin M; Neupane B; Kazmierska P; Betts M; Freitag A; Kiri S; Taieb V; Slim M; Gomez NN; Warren RB
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1777-1792. PubMed ID: 35798920
[TBL] [Abstract][Full Text] [Related]
13. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
[TBL] [Abstract][Full Text] [Related]
14. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
16. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
17. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
18. Review of bimekizumab in the treatment of psoriasis.
Koppu S; Singh R; Kaur K; Feldman SR
Hum Vaccin Immunother; 2022 Nov; 18(6):2119767. PubMed ID: 36094828
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.
Kokolakis G; Ghoreschi K
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]